Associated Papers
Prevalence, genetic variations and clinical outcomes of BRAF-V600 mutated advanced NSCLC in China: a retrospective real-world multi-centre study.
Jia B et al.
Ebiomedicine, 2025
Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study.
Nebhan CA et al.
The Oncologist, 2021
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
32958805 (PubMed )
Supplement: 41598_2020_72404_MOESM2_ESM.xlsx › ClinVar
The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models.
Yen J et al.
Genome Biology, 2013
24148783 (PubMed )
Supplement: gb-2013-14-10-r113-S1.xlsx › Table_S3
Select a paper to view details